

AGM PRESENTATION

November 2023

Andrew Harrison, CEO

Resonance
Health



Our Business – Medical Devices




Resonance has a large complex global footprint of imaging and clinical trial customers.



Customers

- Diagnostic
- Clinical Trials

Core Products

-  **FerriScan[®]**
-  **HepaFatScan[®]**
-  **CardiacT2***

Snapshot

- In 48 Countries
- Over 400 Active Sites
- 90,000 Analysis Completed
- Over 35 clinical trials serviced



Map icons indicate our worldwide imaging locations, with over 400+ active sites.

Our Business – Clinical Trial Services

This trial represents a significant change in scale, an opportunity to expand service offerings, and generate greater revenues from within the clinical trial ecosystem.


- ✓ Resonance was awarded the Sun Pharmaceutical Trial in August 2023.
- ✓ The trial has a contract value of ~\$6.3m over an expected 18-month timeframe.
- ✓ The trial is progressing well with ~\$1.1m revenue invoiced to date.
- ✓ Resonance has built an impressive internal capability and expertise with over a decade of experience in providing imaging services, and several recent key hires.



Our Business – Antisense Oligonucleotide

ASON project represents an opportunity to develop a platform business based on Cyclophilin (A,B,D) inhibition across organ types, diseases, and in combination with other therapies.

- ✓ Using ASO's as a method of treating disease is becoming more common. Significant advances have been made in delivery and toxicity.
- ✓ ASO treatments are Highly Selective and Efficacious, have a Good Safety Profile (FDA Acceptance), and have Improved Patient Compliance (limited dosing needed).
- ✓ RHT's has developed a novel approach using ASO's rather than small drug molecule treatments.
- ✓ Strong IP Protection.
- ✓ Offers a calibrated reduction in specific Cyclophilin production, unlike small molecule drugs which target all cyclophilins in all tissues regardless of whether they are disease related or not.
- ✓ A potential commercialisation pathway is looking at other drugs that may have increased efficacy when used in conjunction with ours.
- ✓ Mouse dosing trials last half FY24 followed by Mouse Liver and Parkinsons models early FY25.



Our Business – Operating Performance

- Revenue up significantly year on year.
- Expected to continue through second half.
- EBITDA significantly up year on year.
- Strong cash balance.
- Strong drive to greater scale and full year profitability.

| | Jul-Sept 23* | FY2023 |
|---|--------------------|----------|
| Revenue | \$2.17M (+107% pc) | \$4.51m |
| Operating EBITDA (ex share-based payments) | \$0.6m | -\$0.80m |
| One off Restructuring costs | ~\$0.3m | - |
| R&D Tax rebate | - | \$0.48m |
| | | |
| Net cash @ 31 Oct 23 | \$6.6m | |

**unaudited management report*

Growth - Existing Business

| | |
|---|--|
| Build Capability (people) | CFO, VP of BD, and the resourcing & reorganising of the R&D and Product Teams to expedite product development pipeline |
| Product Improvements | FerriScan scan time reduction, Cardiac T2* 3T, and others |
| New Products | Liver Fibrosis, Inflammation, and others |
| New Geographies | China, Japan |
| Partnerships | Likeminded SaMD vendors |
| Understanding our customers | Customer research and Seamless PACS integration |
| Greater focus on Clinical Trial markets | Iron Overload, Liver Fat, new products |
| Molecular | ASON |


Clinical Trial Opportunity

This opportunity is underpinned by the over-arching strategy of leveraging clinical trial relationships to gain a greater share of spending within the clinical trial ecosystem.




Clinical Trial Value Drivers

Clinical trials are characterised by more complex requirements resulting in premium prices.



CASES FY23








REVENUE FY23

Clinical Trials in Australia

Australia is a highly attractive clinical trial destination – In 2019 95,000 people participated in over 1,800 trials, a 7% CAGR in trials since 2015. Industry sponsored trials were worth >\$1.12B.

Benefits

- ✓ Approvals and regulatory system.
- ✓ Public private health system.
- ✓ Multi cultural population.
- ✓ Population receptive to testing / participation.
- ✓ Tax system.

| Metric | 2015* | 2019** | CAGR (2015–19) |
|--|-----------------|-----------------|----------------|
|  Expenditure | \$1.1 billion | \$1.4 billion | 5% |
|  Employment | 6,900 employees | 8,000 employees | 4% |
|  Patient participation | Not reported | 95,000 | N/A |
|  Number of trials started | c.1,360 | c.1,880 | 7% |
|  Share of global industry sponsored trials | c.5% | c.5% | Nil |

Note: * As calculated in *Clinical Trials in Australia* (2017) report; ** As calculated in this report

*MTPCONNECT.ORG.AU

MRI Liver Fibrosis / Inflammation Measurement

- Extended proof of concept underway. Results early next calendar year pave the way to partner with global Pharma to use product for investigational purposes in a trial. Both monetizing and moving towards regulatory clearances.

Product Improvements

- FerriScan Shorter acquisition time, 3T Cardiac T2*, direct PACS integration, and others. Designed to broaden customer base and improve customer economics and experience.

M&A in Clinical Trial Ecosystem

- Currently reviewing strong deal pipeline in trial services.

Product Partnerships

- Expands the range of services available for existing customers and develops new customer relationships through mutual reseller agreements. Leverages both diagnostic customer relationships and our clinical trial platform. Initial discussions are underway with the first potential partner.

This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health’s products and services.

These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of or be relied on in any connection with any contract or commitment. The information in this presentation does not take into account the objectives, financial situation or individual needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision.

To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other person’s accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it.